Specifically, unsaturated FAs, including linoleic acids (LA), activate the FABP4/CEBPα pathway, leading to triglyceride synthesis and lipid droplet formation. Furthermore, FABP4 enhances lipolysis and ...

This important paper uses elegant models, including genetic knock outs, to demonstrate that FABP4 contributes to lipid accumulation in tumor-associated macrophages, which seems to increase breast ...

Finally, our preclinical data in a mouse model of MASH and dyslipidemia treated with a FASN inhibitor that is a surrogate for denifanstat showed that a FASN inhibitor may reduce circulating ...

1, Hannover 30625, Germany; engeli.stefan{at}mh-hannover.de Objective To explore whether increased adipocyte-derived serum fatty acid binding protein 4 (FABP4) predisposes to cardiac remodelling and ...

FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: ...

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML ...

FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq ...

(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b ...

GDM is leading to an elevated risk for the development of cardiovascular diseases both in the mother and the child in later life. Previous studies have identified fatty acid-binding protein 4 (FABP4) ...